Exclusive Summary

• **High-Need Niche in Global Shortage**: Essential treatment for Leishmaniasis (a Neglected Tropical Disease), characterized by limited global suppliers and frequent shortages, making it ideal for NGO tenders and government procurement.
• **Guideline-Endorsed Standard of Care**: Listed on the WHO Model List of Essential Medicines (EML) and remains the first-line or core combination therapy in national guidelines across East Africa and South America.
• **Significant Cost-Efficiency**: Offers a drastic price advantage over the branded originator (Pentostam), crucial for accessing markets in developing nations with limited public health budgets.
• **Risk-Free Licensing Opportunity**: With long-expired patents, there are no IP barriers, allowing for immediate tech transfer or commercialization to fill the supply vacuum left by exiting western pharma companies.

Asset Materials

Contact Us for Full Materials